179 related articles for article (PubMed ID: 37193249)
61. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
[TBL] [Abstract][Full Text] [Related]
62. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
63. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
64. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
65. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
[TBL] [Abstract][Full Text] [Related]
66. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
67. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
68. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
69. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.
Fernandez AI; Gavrielatou N; McCann L; Shafi S; Moutafi MK; Martinez-Morilla S; Vathiotis IA; Aung TN; Yaghoobi V; Bai Y; Chan YG; Weidler J; Herbst R; Bates M; Rimm DL
J Thorac Oncol; 2022 Sep; 17(9):1078-1085. PubMed ID: 35764237
[TBL] [Abstract][Full Text] [Related]
70. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
71. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
Front Oncol; 2020; 10():1644. PubMed ID: 32903369
[TBL] [Abstract][Full Text] [Related]
72. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
73. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
74. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
75. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
Wang Y; Niu X; Cheng Y; Zhang Y; Xia L; Xia W; Lu S
Clin Exp Immunol; 2022 Jun; 208(3):316-322. PubMed ID: 35514075
[TBL] [Abstract][Full Text] [Related]
76. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
Vlachostergios PJ
Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
[TBL] [Abstract][Full Text] [Related]
77. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
78. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
79. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
80. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
